Curasight

The international patent application  WO2024/153756 A1 was filed in 2023 and covers the use of additional alpha-emitters and beta-emitters radionuclides in 2023. Existing patents covering the company's technology have previously been granted in the US, Canada, Europe, Japan, China and Hong Kong with protection lasting into 2033. These patents relate to the use of the beta-emitting radionuclide Lutetium-177 (177Lu).

"We are committed to ensuring robust patent protection for our technology as part of our work developing uTREAT as a potential new treatment option for certain types of cancer. This additional patent application could extend patent protection of uTREAT by 19 years until 2043," said Curasight CEO Ulrich Krasilnikoff. "Today's news marks another step in our efforts to bring new treatment options using radioligand therapy and follows our recently announced plans to run a trial with uTREAT in glioblastoma - or brain cancer - where we expect to dose the first patient in late Q2, 2025."

About the application

The patent application (international publication WO2024/153756 A1) covers the use of additional radionuclides - both alpha-emitters and beta-emitters. The alpha-emitters covered by the application include Actinium-225 (225Ac), Lead-212 (212Pb), and Terbium-149 (149Tb). For beta-emitters, Copper-67 (67Cu), and Terbium-161 (161Tb) are now covered in addition to the previously granted patents on 177Lu.

About Curasight's theranostic platform

Curasight's radiopharmaceutical theranostic platform builds on uPAR-targeting peptides labelled either with radioisotopes suitable for imaging, uTRACE®, or labelled with radioisotopes suitable for radioligand therapy, uTREAT®. The target, uPAR, is expressed in the majority of solid tumors and is a marker of cancer aggressiveness.